Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources
- 7 January 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (3) , 1612-1661
Abstract
Strong opioid analgesics, including morphine, are the mainstays for treating moderate to severe acute pain and alleviating chronic cancer pain. However, opioid-related adverse effects, including nausea or vomiting, sedation, respiratory depression, constipation, pruritus (itch), analgesic tolerance, and addiction and abuse liability, are problematic. In addition, the use of opioids to relieve chronic noncancer pain is controversial due to the “opioid crisis” characterized by opioid misuse or abuse and escalating unintentional death rates due to respiratory depression. Hence, considerable research internationally has been aimed at the “Holy Grail” of the opioid analgesic field, namely the discovery of novel and safer opioid analgesics with improved opioid-related adverse effects. In this Perspective, medicinal chemistry strategies are addressed, where structurally diverse nonmorphinan-based opioid ligands derived from natural sources were deployed as lead molecules. The current state of play, clinical or experimental status, and novel opioid ligand discovery approaches are elaborated in the context of retaining analgesia with improved safety and reduced adverse effects, especially addiction liability.Keywords
Funding Information
- University of Queensland
This publication has 175 references indexed in Scilit:
- CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis studyNeuroscience Letters, 2012
- Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacologyDrug and Alcohol Dependence, 2012
- Unexpected Opioid Activity Profiles of Analogues of the Novel Peptide Kappa Opioid Receptor Ligand CJ‐15,208ChemMedChem, 2011
- Structure-Based Design, Synthesis, and Biochemical and Pharmacological Characterization of Novel Salvinorin A Analogues as Active State Probes of the κ-Opioid ReceptorBiochemistry, 2009
- Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptidesBioorganic & Medicinal Chemistry, 2008
- Herkinorin Analogues with Differential β-Arrestin-2 InteractionsJournal of Medicinal Chemistry, 2008
- Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodynEuropean Journal of Pharmacology, 2007
- In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptorPeptides, 2007
- The dermorphin peptide familyGeneral Pharmacology: The Vascular System, 1996
- On the degradation of dermorphin and D-Arg2-dermorphin analogs by a soluble rat brain extractBiochemical and Biophysical Research Communications, 1985